150 related articles for article (PubMed ID: 9731223)
1. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
2. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study.
Bromek E; Haduch A; Daniel WA
Eur J Pharmacol; 2010 Jan; 626(2-3):171-8. PubMed ID: 19818757
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
5. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver.
Chow T; Imaoka S; Hiroi T; Funae Y
Drug Metab Dispos; 1999 Feb; 27(2):188-92. PubMed ID: 9929501
[TBL] [Abstract][Full Text] [Related]
6. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
[TBL] [Abstract][Full Text] [Related]
7. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
8. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human and cynomolgus monkey cytochrome P450 2E1 enzymes.
Hanioka N; Yamamoto M; Iwabu H; Jinno H; Tanaka-Kagawa T; Naito S; Shimizu T; Masuda K; Katsu T; Narimatsu S
Life Sci; 2007 Oct; 81(19-20):1436-45. PubMed ID: 17935737
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling.
Zhu W; Mantione KJ; Shen L; Cadet P; Esch T; Goumon Y; Bianchi E; Sonetti D; Stefano GB
Med Sci Monit; 2005 Nov; 11(11):BR397-404. PubMed ID: 16258388
[TBL] [Abstract][Full Text] [Related]
11. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
12. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.
Kasahara M; Suzuki H; Komiya I
Drug Metab Dispos; 2000 Apr; 28(4):409-17. PubMed ID: 10725309
[TBL] [Abstract][Full Text] [Related]
13. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
[TBL] [Abstract][Full Text] [Related]
14. Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox.
Wassenberg T; Willemsen MA; Geurtz PB; Lammens M; Verrijp K; Wilmer M; Lee WT; Wevers RA; Verbeek MM
Mol Genet Metab; 2010 Dec; 101(4):349-56. PubMed ID: 20832343
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
Baranczewski P; Edlund PO; Postlind H
J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 mediates dopamine formation in the brain in vivo.
Bromek E; Haduch A; GoĊembiowska K; Daniel WA
J Neurochem; 2011 Sep; 118(5):806-15. PubMed ID: 21651557
[TBL] [Abstract][Full Text] [Related]
18. Effect of Cytochrome P450 (CYP) 2D6 Genetic Polymorphism on the Inhibitory Action of Antidepressants on CYP2D6-Mediated Dopamine Formation from p-Tyramine.
Niwa T; Yanai M; Matsumoto M; Shizuku M
J Pharm Pharm Sci; 2018; 21(1):135-142. PubMed ID: 29602316
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
20. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes.
Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L
Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
